Latest news with #EmilyField
CNBC
2 days ago
- Business
- CNBC
Field: Investors are breathing a sigh of relief at the 15% tariff level
Emily Field, Barclays head of European pharma research, tells Worldwide Exchange tariffs bring relief at 15%, but risks like shortages and pricing still weigh on the sector.
Al Etihad
3 days ago
- Business
- Al Etihad
Novo Nordisk faces 'show me' moment to boost Wegovy growth after US copycat ban
28 July 2025 14:38 LONDON (REUTERS)A US ban on copycat versions of Novo Nordisk's Wegovy has begun to lift use of the weight loss drug, but the company will need to show more robust growth in the months ahead to bolster market confidence, investors and analysts Wegovy prescriptions have increased by about 33% since May 22, when a US Food and Drug Administration ban on so-called compounded versions of Wegovy took effect, amounting to 181,200 in the week ended July 18, according to data from IQVIA that was shared with Reuters by industry Wegovy prescriptions have also increased, narrowing the lead for Eli Lilly and Co's Zepbound. In the week ended May 23, U.S. Zepbound prescriptions exceeded Wegovy by nearly 175,000. By July 18, the gap was about 133, signs of a shift come at a critical juncture for Novo. After Wegovy's initial stunning success, investor confidence was rattled when Zepbound and compounders started to slow the drug's then in May, the Danish company cut its full-year sales and earnings forecasts and announced the surprise exit of Chief Executive Lars Fruergaard Jorgensen, citing market challenges and a stock price nearly 60% below its 2024 said at the time he expected the FDA compounding ban to lift sales in the second half of this year. Investors are keen to hear whether that is still likely when the company reports quarterly earnings on August leaves the drugmaker in what Barclays analyst Emily Field called a "show me" phase - no longer buoyed by optimism about a turnaround but under pressure to sales of Wegovy catapulted Novo to become Europe's most valuable listed company, peaking in June 2024 at about 615 billion euros, after the weekly injection became the first highly-effective obesity treatment approved in the US in supply disruptions and gaps in health insurance coverage for Wegovy helped fuel the market for cheaper compounded - or copycat - versions, which are allowed under US law when drugs are in sentiment on Novo soured after the company lost ground to US rival Eli Lilly, which launched Zepbound in late its first full-year forecast downgrade since Wegovy's launch, Novo said in May it expected local-currency sales growth of 13-21%, down from a previous forecast of 16-24%. Operating profit growth is projected at 16-24%, versus 19-27% more of the patients who had turned to compounded drugs is key to meeting those targets. The FDA determined that Wegovy was no longer in shortage in February, leading to the ban on compounded versions. Novo has rolled out new tactics to bring patients back, including a limited-time discount for one month's supply, and secured better coverage from insurer CVS Health.
CNBC
14-07-2025
- Business
- CNBC
Barclays: The pharma sector is very out of favor for tariffs
Emily Field, head of European pharma research at Barclays, discusses which drug makers would be most impacted by 30% U.S. tariffs on EU imports, and the likelihood President Trump moves ahead with up to 200% tariffs on foreign pharma products.
Globe and Mail
10-07-2025
- Business
- Globe and Mail
Barclays Sticks to Their Hold Rating for GlaxoSmithKline (GSK)
Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline today and set a price target of £14.50. The company's shares closed yesterday at p1,414.00. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. According to TipRanks, Field is an analyst with an average return of -2.1% and a 37.76% success rate. Field covers the Healthcare sector, focusing on stocks such as GlaxoSmithKline, AstraZeneca, and Roche Holding AG. In addition to Barclays, GlaxoSmithKline also received a Hold from Deutsche Bank 's Emmanuel Papadakis in a report issued yesterday. However, on June 30, J.P. Morgan maintained a Sell rating on GlaxoSmithKline (LSE: GSK). Based on GlaxoSmithKline's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of p7.52 billion and a net profit of p1.62 billion. In comparison, last year the company earned a revenue of p7.36 billion and had a net profit of p1.05 billion Based on the recent corporate insider activity of 311 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of GSK in relation to earlier this year.
Business Insider
09-07-2025
- Business
- Business Insider
Barclays Sticks to Their Hold Rating for GlaxoSmithKline (GSK)
Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline today and set a price target of £14.50. The company's shares closed yesterday at p1,414.00. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. According to TipRanks, Field is an analyst with an average return of -2.1% and a 37.76% success rate. Field covers the Healthcare sector, focusing on stocks such as GlaxoSmithKline, AstraZeneca, and Roche Holding AG. In addition to Barclays, GlaxoSmithKline also received a Hold from Deutsche Bank 's Emmanuel Papadakis in a report issued yesterday. However, on June 30, J.P. Morgan maintained a Sell rating on GlaxoSmithKline (LSE: GSK). Based on GlaxoSmithKline's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of p7.52 billion and a net profit of p1.62 billion. In comparison, last year the company earned a revenue of p7.36 billion and had a net profit of p1.05 billion Based on the recent corporate insider activity of 311 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of GSK in relation to earlier this year.
